SinoVision Secures RMB 200 Million Joint Investment to Accelerate Multidisciplinary Clinical Development and Application of CT Technologies

VCBeat (WeChat ID: vcbeat) has exclusively learned that Sinovision Technology (Beijing) Co., Ltd. (hereinafter referred to as “Sinovision”) recently announced it had secured RMB 200 million in joint investment from three investors: Yili Fuyi Daohe, Huagai Medical, and Qiming Venture Partners.

Mr. Fu Shinong, Founder and CEO of Sinovision Technology (Beijing) Co., Ltd., stated, “The successful completion of this financing round in a short period of time is attributable to Sinovision’s steadfast adherence to the product philosophy of ‘Quality Manufacturing in China’ and the market’s high recognition of our dedication to product R&D and technological innovation. Over the past year, installations of Sinovision’s Precision Wide-Angle CT series have been rolled out successively across all provinces in China, with the number of installations steadily increasing. Our customer base extensively covers public hospitals at secondary and tertiary levels, as well as private general and specialized hospitals. Moving forward, we will continue to refine our capabilities, develop more medical imaging products tailored to market needs, and deliver valuable products and services to a broader range of users.”

Sinovision is a dark horse in the CT field, focusing on the research and development and production of CT technology.Since its establishment in 2012, Sinovision has invested over RMB 30 million annually in research and development. Currently, its R&D team, composed of leading elites from the domestic and international medical imaging industries, accounts for 64% of the company’s total workforce. This dual guarantee of funding and talent has laid a solid foundation for Sinovision to develop two to three new products and technologies each year.Sinovision remains firmly focused on core CT technologies, continuously expanding its product portfolio to promote the application of imaging in clinical treatment and drive the development of China’s healthcare industry.

Since its establishment in 2012, Sinovision has received angel investment from Mr. Ju Xiaoping, and subsequently secured investments from Chende Investment Partnership and Jinpu Health Fund around 2014 and 2015.

To date, Sinovision has independently developed a series of CT products, including 16-slice, 32-slice, and 64-slice (128-layer) models, overcoming core technologies such as CT detectors. In the future, it will continue to achieve breakthroughs in the design and development of other key components, such as X-ray tubes.

Meanwhile, Sinovision Technology (Beijing) Co., Ltd. has continued to attract significant attention from industry experts and leaders. Zhao Zilin, Chairman of the China Association of Medical Equipment, expressed optimism about the prospects of domestically produced CT scanners, projecting that they will capture a 50% market share by 2025. Chairman Zhao encouraged Sinovision to persist in independent research and development, always prioritizing innovation and centering on quality, to continuously develop more and better products.

Sinovision believes that over the next decade, CT will be more widely applied in cutting-edge clinical areas such as interventional therapy, precision radiotherapy, and additive manufacturing of implants. The rapid advancement of imaging technology will serve as a powerful driver propelling medical technology to new heights.Sinovision has always adhered to adding value around CT, continuously bringing new value to users.

To date, Sinovision has obtained international certifications such as the CE mark and has reached industrial cooperation intentions with more than ten leading medical technology institutions both domestically and internationally, including those in India, Italy, South Korea, Canada, the United States, Germany, Japan, and Taiwan. In the near future, in addition to conventional imaging diagnosis, Sinovision’s Jing Guangjiao (Wide-Angle) series of CT scanners will demonstrate their outstanding performance in interventional therapy, precision radiotherapy, and 3D printing of implants.

Yili Fuyi Daohé Medical FundMr. Li Yinjia, Founding Partner, stated, “We are honored to serve as the lead investor in this financing round. Sinovision is China’s most promising medical imaging equipment company, boasting an experienced team and sustainable independent R&D capabilities. Its current product performance is already competitive with top-tier global manufacturers. We believe that Sinovision will become a world-class CT manufacturer, not only in China but globally.”

one of the investorsHuagai Healthcare FundIt is an equity investment fund dedicated to the healthcare industry, focusing on biopharmaceuticals, medical devices, and healthcare services. The fund prioritizes industry M&A and consolidation within the healthcare sector, as well as investment opportunities in high-tech enterprises with rapid growth potential at early-to-mid stages. With cumulative assets under management amounting to billions of RMB, the fund was jointly established by over 30 listed companies in the healthcare sector, multiple large financial and insurance institutions, funds of funds (FOFs), and government guidance funds.

Huagai Medical focuses on high-end and cutting-edge technologies, particularly targeting premium medical imaging enterprises like Sinovision Technology (Beijing) Co., Ltd., which boast prominent product technology advantages and strong R&D capabilities. By leveraging Huagai Capital’s industrial influence and extensive resource network within China’s healthcare sector, we aim to enhance interactions across the industry chain, further create value-added opportunities, respond to national calls, support the domestic substitution of medical devices, and jointly foster a new landscape for China’s healthcare industry.Responsible for this transactionHuagai MedicalManaging Partner Zeng Zhiqiang and Investment Director Meng Nan stated, “Compared with giants such as GPS (GE, Philips, and Siemens), although domestic medical imaging equipment manufacturers are relatively smaller in scale, have more limited product portfolios, and still lag behind in cutting-edge technologies, the gap has been gradually narrowing in recent years. Several major domestic imaging players have emerged prominently, and a cohort of outstanding equipment manufacturers has arisen in various niche segments. Meanwhile, domestic equipment vendors have maintained their advantage of rapid market responsiveness, enabling them to iterate and upgrade products more effectively and swiftly based on the needs of specialist physicians.”

“We are pleased to join our partner fund in investing in Sinovision Technology.”Qiming Venture PartnersYin Jie, Executive Director, stated, “China’s market for large-scale diagnostic imaging equipment has long been monopolized by high-priced imported products. Through arduous efforts, the founding team of Sinovision Technology (Beijing) Co., Ltd. has brought its domestic brand to parity with imported brands in terms of quality, user experience, and service. This has delivered high-quality, cost-effective medical experiences to Chinese doctors and patients, while also alleviating the burden on the national healthcare insurance system. We highly recognize the vision, experience, and capabilities demonstrated by the Sinovision team in the development of high-end medical equipment. Qiming Venture Partners will continue to support visionary and focused teams in their pursuit of realizing their dreams!”